loading page

Urinary eicosanoids in T2-low severe asthma: relationship with symptoms and exacerbation profile
  • +20
  • Eastwood M,
  • John Busby,
  • Johan Kolmert,
  • Javier Zurita,
  • Sven-Erik Dahlén,
  • Pamela McDowell,
  • Bradley J,
  • David Jackson,
  • Ian Pavord,
  • Ratko Djukanovic,
  • Arron JR,
  • Peter Bradding,
  • Brightling CE,
  • Rekha Chaudhuri,
  • Douglas Cowan,
  • Stephen Fowler,
  • Hardman TC,
  • Holweg CTJ,
  • Lordan J,
  • Adel Mansur H,
  • Robinson DS,
  • Craig Wheelock,
  • Liam Heaney
Eastwood M
Queen's University Belfast School of Medicine Dentistry and Biomedical Sciences
Author Profile
John Busby
Queen's University Belfast School of Medicine Dentistry and Biomedical Sciences
Author Profile
Johan Kolmert
Karolinska Institutet Forsakringsmedicin
Author Profile
Javier Zurita
Karolinska Institutet Forsakringsmedicin
Author Profile
Sven-Erik Dahlén
Karolinska Institutet Forsakringsmedicin
Author Profile
Pamela McDowell
Queen's University Belfast School of Medicine Dentistry and Biomedical Sciences
Author Profile
Bradley J
Queen's University Belfast School of Medicine Dentistry and Biomedical Sciences
Author Profile
David Jackson
Guy's and St Thomas' NHS Foundation Trust
Author Profile
Ian Pavord
University of Oxford Nuffield Department of Medicine
Author Profile
Ratko Djukanovic
NIHR Southampton Biomedical Research Centre
Author Profile
Arron JR
University of California San Francisco
Author Profile
Peter Bradding
University of Leicester Department of Respiratory Sciences
Author Profile
Brightling CE
University of Leicester Department of Respiratory Sciences
Author Profile
Rekha Chaudhuri
NHS Greater Glasgow and Clyde Public Health Directorate
Author Profile
Douglas Cowan
NHS Greater Glasgow and Clyde
Author Profile
Stephen Fowler
The University of Manchester Division of Infection Immunity and Respiratory Medicine
Author Profile
Hardman TC
Niche Generics Limited
Author Profile
Holweg CTJ
AbbVie Inc Mettawa
Author Profile
Lordan J
Newcastle Upon Tyne Hospitals NHS Foundation Trust
Author Profile
Adel Mansur H
University Hospitals Birmingham NHS Foundation Trust
Author Profile
Robinson DS
University College Hospital Women's Health Service
Author Profile
Craig Wheelock
Karolinska Institutet Forsakringsmedicin
Author Profile
Liam Heaney
Queen's University Belfast School of Medicine Dentistry and Biomedical Sciences

Corresponding Author:[email protected]

Author Profile

Abstract

BACKGROUND: 5-10% of patients with asthma have severe disease. Many patients experience persistent symptoms despite being T2-low. Obesity is associated with increased asthma symptoms. Eicosanoids have well-described roles in the pathophysiology of asthma and may contribute to persistent symptoms in T2-low severe asthma. OBJECTIVE: To examine the relationship between urinary eicosanoids, asthma symptoms, obesity and T2-biomarkers in severe asthma. METHODS: Urine samples were collected during a randomized controlled trial assessing corticosteroid optimization using T2-biomarker directed care at scheduled study visits (n=728) and at exacerbation (n=103). Eicosanoid concentrations were quantified from urine samples using mass-spectrometry. Metabolite concentrations were log 2-transformed, z-scored and concentrated by pathway to generate 6 pathway scores. Results were stratified by T2-biomarker status (T2-Low: fractional-exhaled nitric-oxide [FeNO]<20ppb AND blood eosinophil count [BEC]<0.15x10 9cells/L) vs T2-high: (FeNO≥20ppb AND BEC≥0.15x10 9cells/L), symptoms (symptom-low: Asthma control Questionnaire-7 (ACQ-7)<1.5)] vs symptom-high [ACQ-7≥1.5]), and obesity. RESULTS: The cysteinyl-leukotriene (CysLT) pathway score was elevated in T2-high versus T2-low participants (P=0.0007), regardless of symptom burden. The isoprostane pathway score was higher in symptom-high versus symptom-low participants, regardless of T2-status (P=0.01). Higher isoprostane (P=0.02) and thromboxane (P=0.04) pathway scores were associated with increased symptoms in T2-low participants. Corticosteroid exposure, obesity and exacerbations were not associated with raised pathway scores (P≥0.05). CONCLUSION: Thromboxane pathway metabolites were elevated in symptom-high/T2-low participants whereas isoprostane pathway metabolites were associated with increased symptoms, regardless of T2-status. These pathways are not affected by CS exposure. Further research is needed to define the role of eicosanoids in T2-low severe asthma using interventions to perturb these pathways.
Submitted to Allergy
Submission Checks Completed
Assigned to Editor
Reviewer(s) Assigned
22 Jun 2024Review(s) Completed, Editorial Evaluation Pending